Clinical trial · Interventional
Radiotherapy With Humidification in Head And Neck Cancer
A Randomised Phase III Trial of Radiotherapy With Humidification in Head And Neck Cancer
NCT01917942CI-TRIAL-00028585RadioHumcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a two arm randomised phase III trial which will evaluate prospectively the benefits of humidification in patients receiving radiotherapy / chemoradiation for head and neck cancer. The intent of humidification is to moisturise the mucosa. The rationale for the use of humidification with radiotherapy can be considered an extension of the general principle of moist wound care in wound management.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of the Head and Neck | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Humidification | Device | — | UNRESOLVED |
| Standard of Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard of Care
- description
- Standard of Care
- interventionNames
- Other: Standard of Care
- type
- EXPERIMENTAL
- label
- Humidification
- description
- Humidification
- interventionNames
- Device: Humidification
Primary outcomes (1)
- measure
- Intensity of mucositis as a function of time for CTCAE grade > 1 mucositis (e.g. grade 2 or higher) measured as the area under the time curve (AUC) of the plot expressing grade of acute reactions vs weeks for observed CTCAE mucosal reactions > 1.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients who meet the following criteria will be eligible: * Pathologically confirmed diagnosis of cancer involving the Nasopharynx, Oropharynx, Oral Cavity, Larynx, or Hypopharynx * Regional nodal irradiation included in PTV1 (as a minimum ipsilateral levels II-III) * Prescribed dose of radiotherapy is at least 60 Gy * Receiving definitive or post-operative adjuvant Radiotherapy * Receiving Radiotherapy as sole modality or Chemoradiation * Patient \> 18 years old * Available for follow-up for up to 2 years * Life expectancy greater than 6 months * Written informed consent * Participation of patients on other clinical trial protocols permitted Exclusion Criteria: Patients who meet the following criteria will be excluded: * Presence of tracheostomy or stoma * Diagnosis of T1 / T2 glottic carcinoma * Undergoing CPAP therapy -Treatment with Amifostine or Palifermin (keratinocyte growth factor) during radiotherapy * History of previous radiotherapy to the head and neck region, excluding superficial radiotherapy to cutaneous squamous cell carcinoma or basal cell carcinoma * High risk for poor compliance with radiotherapy, humidification, or follow-up as assessed by the investigator
References
Publications (0)
Data not yet available
No reference posted for this study.